BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Clinical Outcome
19 results:

  • 1. High p16 expression and heterozygous rb1 loss are biomarkers for CDK4/6 inhibitor resistance in ER
    Palafox M; Monserrat L; Bellet M; Villacampa G; Gonzalez-Perez A; Oliveira M; Brasó-Maristany F; Ibrahimi N; Kannan S; Mina L; Herrera-Abreu MT; Òdena A; Sánchez-Guixé M; Capelán M; Azaro A; Bruna A; Rodríguez O; Guzmán M; Grueso J; Viaplana C; Hernández J; Su F; Lin K; Clarke RB; Caldas C; Arribas J; Michiels S; García-Sanz A; Turner NC; Prat A; Nuciforo P; Dienstmann R; Verma CS; Lopez-Bigas N; Scaltriti M; Arnedos M; Saura C; Serra V
    Nat Commun; 2022 Sep; 13(1):5258. PubMed ID: 36071033
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
    Galardi F; De Luca F; Biagioni C; Migliaccio I; Curigliano G; Minisini AM; Bonechi M; Moretti E; Risi E; McCartney A; Benelli M; Romagnoli D; Cappadona S; Gabellini S; Guarducci C; Conti V; Biganzoli L; Di Leo A; Malorni L
    Breast Cancer Res; 2021 Mar; 23(1):38. PubMed ID: 33761970
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
    Pancholi S; Ribas R; Simigdala N; Schuster E; Nikitorowicz-Buniak J; Ressa A; Gao Q; Leal MF; Bhamra A; Thornhill A; Morisset L; Montaudon E; Sourd L; Fitzpatrick M; Altelaar M; Johnston SR; Marangoni E; Dowsett M; Martin LA
    Oncogene; 2020 Jun; 39(25):4781-4797. PubMed ID: 32307447
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism.
    Zhang Z; Li J; Ou Y; Yang G; Deng K; Wang Q; Wang Z; Wang W; Zhang Q; Wang H; Sun W; Sun P; Yang S
    Signal Transduct Target Ther; 2020 Mar; 5(1):25. PubMed ID: 32296027
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Molecular stratification within triple-negative breast cancer subtypes.
    Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
    Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in rb1, MYC, and Wnt signaling.
    Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
    Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on clinical outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma.
    Sato S; Nagahashi M; Koike T; Ichikawa H; Shimada Y; Watanabe S; Kikuchi T; Takada K; Nakanishi R; Oki E; Okamoto T; Akazawa K; Lyle S; Ling Y; Takabe K; Okuda S; Wakai T; Tsuchida M
    Sci Rep; 2018 Jan; 8(1):1005. PubMed ID: 29343775
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.
    Milea A; George SH; Matevski D; Jiang H; Madunic M; Berman HK; Gauthier ML; Gallie B; Shaw PA
    Mod Pathol; 2014 Jul; 27(7):991-1001. PubMed ID: 24336157
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas.
    Bogina GS; Lunardi G; Marcolini L; Brunelli M; Bortesi L; Marconi M; Coati F; Valerio M; Guerriero M; Massocco A; Pegoraro MC; Zamboni G
    Mod Pathol; 2014 Feb; 27(2):204-13. PubMed ID: 23887295
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. FoxM1 regulates mammary luminal cell fate.
    Carr JR; Kiefer MM; Park HJ; Li J; Wang Z; Fontanarosa J; DeWaal D; Kopanja D; Benevolenskaya EV; Guzman G; Raychaudhuri P
    Cell Rep; 2012 Jun; 1(6):715-29. PubMed ID: 22813746
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Tumour suppressor genes in chemotherapeutic drug response.
    Lai D; Visser-Grieve S; Yang X
    Biosci Rep; 2012 Aug; 32(4):361-74. PubMed ID: 22762204
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Prognostic significance of rb1-inducible coiled-coil 1 in salivary gland cancers.
    Tameno H; Chano T; Ikebuchi K; Ochi Y; Arai A; Kishimoto M; Shimada T; Hisa Y; Okabe H
    Head Neck; 2012 May; 34(5):674-80. PubMed ID: 21717524
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.
    Fordyce C; Fessenden T; Pickering C; Jung J; Singla V; Berman H; Tlsty T
    Cancer Prev Res (Phila); 2010 Feb; 3(2):190-201. PubMed ID: 20028875
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein.
    Derenzini M; Brighenti E; Donati G; Vici M; Ceccarelli C; Santini D; Taffurelli M; Montanaro L; Treré D
    J Pathol; 2009 Nov; 219(3):373-82. PubMed ID: 19731257
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts.
    Sotgia F; Del Galdo F; Casimiro MC; Bonuccelli G; Mercier I; Whitaker-Menezes D; Daumer KM; Zhou J; Wang C; Katiyar S; Xu H; Bosco E; Quong AA; Aronow B; Witkiewicz AK; Minetti C; Frank PG; Jimenez SA; Knudsen ES; Pestell RG; Lisanti MP
    Am J Pathol; 2009 Mar; 174(3):746-61. PubMed ID: 19234134
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
    Travaglini L; Vian L; Billi M; Grignani F; Nervi C
    Int J Biochem Cell Biol; 2009 Jan; 41(1):225-34. PubMed ID: 18789398
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy.
    Mercier I; Casimiro MC; Wang C; Rosenberg AL; Quong J; Minkeu A; Allen KG; Danilo C; Sotgia F; Bonuccelli G; Jasmin JF; Xu H; Bosco E; Aronow B; Witkiewicz A; Pestell RG; Knudsen ES; Lisanti MP
    Cancer Biol Ther; 2008 Aug; 7(8):1212-25. PubMed ID: 18458534
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure.
    Derenzini M; Donati G; Mazzini G; Montanaro L; Vici M; Ceccarelli C; Santini D; Taffurelli M; Treré D
    Clin Cancer Res; 2008 Apr; 14(7):2199-209. PubMed ID: 18381962
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Relationship between the rb1 mRNA level and the expression of phosphorylated RB protein in human breast cancers: their relevance in cell proliferation activity and patient clinical outcome.
    Derenzini M; Montanaro L; Vici M; Barbieri S; Ceccarelli C; Santini D; Taffurelli M; Martinelli GN; Treré D
    Histol Histopathol; 2007 May; 22(5):505-13. PubMed ID: 17330805
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.